Revenio Group Corporation: REVENIO AIMS TO LAUNCH SCREENING DEVICE TO DETECT SKIN CANCER

Revenio Group Corporation Stock Exchange Release, January 21, 2015 at 9:00 am


REVENIO AIMS TO LAUNCH SCREENING DEVICE TO DETECT SKIN CANCER

Revenio to cooperate with VTT Technical Research Centre of Finland and
University of Jyväskylä to commercialize technology for skin cancer screening

The Revenio Group Corporation has signed a license agreement with VTT Technical
Research Centre of Finland concerning intellectual property rights and know-how
regarding the hyperspectral camera technology developed by VTT. Under the
agreement, Revenio will license the technology, know-how, documentation,
software, inventions and associated patent rights relating to VTT's
hyperspectral camera. Revenio has also signed a cooperation agreement with VTT
on commercialization of a hyperspectral imaging system suitable for skin cancer
diagnostics and with the University of Jyväskylä on commercialization of the
invention relating to the software code. During 2015, Revenio and VTT will
develop second generation prototypes of the hyperspectral camera. The final
schedule for the project will become clearer in the light of experience gained.
Revenio aims to launch an easy-to-use, mobile screening device for
dermatologists to use to detect skin cancers and their precursors. According to
the company's current view, the screening device is not expected to generate
significant commercial value for a few years.

"The license agreement we have signed will provide us with an opportunity to
make an easy-to-use, mobile screening device to detect skin changes at an early
stage available to dermatologists quickly and cost-effectively. Once again we
are dealing with issues that are important to us - improving the quality of
people's lives and lowering the costs of health care. At Revenio, we will
continue to focus on our current range of products, in line with our strategy,
and increasingly on screening-related products. With these products we aim to
meet global public health challenges where common denominators are the need to
make cost savings in health care through preventive measures. Screening and
follow-up hold a significant role in preventive work and it is here that we want
to play a key role," says the Revenio Group's President and CEO Olli-Pekka
Salovaara.

"VTT has developed the adjustable filter technology determinedly for a number of
years now. It has an extremely wide range of use in various measurement and
imaging applications and business operations have already developed around the
technology. The cooperation with Revenio will open up wider possibilities for
using the method in health tech applications - also an important growth area for
VTT. This is a good example of how Finnish businesses can be created through
VTT's technology," comments Petri Kalliokoski, Executive Vice President,
Knowledge Intensive Products and Services.

The basic invention, a spectral imaging device made up of a so-called Fabry-
Pérot filter and a camera, was developed by Heikki Saari, Principal Scientist at
VTT, some ten years ago and it has numerous different potential applications.
VTT developed the hyperspectral camera which utilizes the technology to detect
skin changes caused by skin cancer on the basis of an idea of Professor Pekka
Neittaanmäki. The first generation prototypes of the hyperspectral camera have
been in trial use at the dermatology department of a Finnish hospital for over a
year, and the results are very encouraging. The prototype has already received a
great deal of publicity in Finland, with the technology magazine Tekniikan
Maailma (No.11/2014) and the Finnish daily Helsingin Sanomat (October 10, 2014)
featuring articles on the technology.

Skin cancers and their precursors are increasingly rapidly throughout the world.
The underlying cause of various skin changes lies in continuously increasing
exposure to UV radiation. The earlier skin cancer is detected, the lower the
mortality rate and costs incurred to society.

Revenio Group Corporation
Olli-Pekka Salovaara
President & CEO

For additional information, please contact
President & CEO Olli-Pekka Salovaara, tel. +358 40 567 5520
olli-pekka.salovaara@revenio.fi
http://www.revenio.fi

DISTRIBUTION:
NASDAQ OMX Helsinki
Financial Supervisory Authority (FIN-FSA)
Principal media
http://www.revenio.fi


The Revenio Group in brief

Revenio is a Finnish health tech group whose core business lies in screening.
The Revenio Health Tech segment comprises the business operations of Icare
Finland Oy and Oscare Medical Oy, which specializes in osteoporosis screening,
monitoring and diagnosis. In addition, Revenio has identified new growth
opportunities relating to health tech in which common denominators are
screening, follow-up and the global need to make cost savings in health care
through preventive measures. Revenio seeks vigorous growth in health technology,
both organically and through acquisitions and mergers.

In 2013, the Revenio Group's net sales totaled MEUR 25.7, with its operating
margin standing at 21.7%. The Revenio Group Corporation is listed on NASDAQ OMX
Helsinki.


[HUG#1888493]